Compile Data Set for Download or QSAR
Found 50 Enz. Inhib. hit(s) with all data for entry = 50009907
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089055(CHEMBL273811 | N*2*-(4-Ethanesulfonylmethyl-phenyl...)
Show SMILES CCS(=O)(=O)Cc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C23H22N4O2S/c1-2-30(28,29)16-17-12-14-19(15-13-17)25-23-26-21-11-7-6-10-20(21)22(27-23)24-18-8-4-3-5-9-18/h3-15H,2,16H2,1H3,(H2,24,25,26,27)
Affinity DataIC50: 0.600nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089048(CHEMBL18163 | N,N-Dimethyl-C-[4-(4-phenylamino-qui...)
Show SMILES CN(C)S(=O)(=O)Cc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C23H23N5O2S/c1-28(2)31(29,30)16-17-12-14-19(15-13-17)25-23-26-21-11-7-6-10-20(21)22(27-23)24-18-8-4-3-5-9-18/h3-15H,16H2,1-2H3,(H2,24,25,26,27)
Affinity DataIC50: 0.900nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Rat 6B)
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 1.40nMAssay Description:Compound was tested for rat Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089069(CHEMBL17632 | N-[4-(4-Phenylamino-quinazolin-2-yla...)
Show SMILES CS(=O)(=O)NC[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ccccc2n1
Show InChI InChI=1S/C22H27N5O2S/c1-30(28,29)23-15-16-11-13-18(14-12-16)25-22-26-20-10-6-5-9-19(20)21(27-22)24-17-7-3-2-4-8-17/h2-10,16,18,23H,11-15H2,1H3,(H2,24,25,26,27)/t16-,18-
Affinity DataIC50: 2nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089060(CHEMBL273597 | Naphthalene-1-sulfonic acid [4-(4-a...)
Show SMILES Nc1nc(N[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C25H27N5O2S/c26-24-21-9-3-4-10-22(21)29-25(30-24)28-19-14-12-17(13-15-19)16-27-33(31,32)23-11-5-7-18-6-1-2-8-20(18)23/h1-11,17,19,27H,12-16H2,(H3,26,28,29,30)/t17-,19-
Affinity DataIC50: 2.70nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 2.90nMAssay Description:Compound was tested for its antagonistic activity against Neuropeptide Y receptor Y5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 2.90nMAssay Description:Compound was tested for human Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089036(CHEMBL278881 | Naphthalene-1-sulfonic acid {4-[2-(...)
Show SMILES Nc1nc(NCC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C27H31N5O2S/c28-26-23-9-3-4-10-24(23)31-27(32-26)29-17-16-19-12-14-20(15-13-19)18-30-35(33,34)25-11-5-7-21-6-1-2-8-22(21)25/h1-11,19-20,30H,12-18H2,(H3,28,29,31,32)/t19-,20-
Affinity DataIC50: 2.90nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089070(4-Methyl-N-[4-(4-phenylamino-quinazolin-2-ylamino)...)
Show SMILES Cc1ccc(cc1)S(=O)(=O)NC[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ccccc2n1
Show InChI InChI=1S/C28H31N5O2S/c1-20-11-17-24(18-12-20)36(34,35)29-19-21-13-15-23(16-14-21)31-28-32-26-10-6-5-9-25(26)27(33-28)30-22-7-3-2-4-8-22/h2-12,17-18,21,23,29H,13-16,19H2,1H3,(H2,30,31,32,33)/t21-,23-
Affinity DataIC50: 4nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089065(CHEMBL279408 | N*2*-(4-Diethylamino-phenyl)-N*4*-p...)
Show SMILES CCN(CC)c1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C24H25N5/c1-3-29(4-2)20-16-14-19(15-17-20)26-24-27-22-13-9-8-12-21(22)23(28-24)25-18-10-6-5-7-11-18/h5-17H,3-4H2,1-2H3,(H2,25,26,27,28)
Affinity DataIC50: 4nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089063(Acetic acid 4-(4-phenylamino-quinazolin-2-ylamino)...)
Show SMILES CC(=O)O[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ccccc2n1
Show InChI InChI=1S/C22H24N4O2/c1-15(27)28-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-16-7-3-2-4-8-16/h2-10,17-18H,11-14H2,1H3,(H2,23,24,25,26)/t17-,18-
Affinity DataIC50: 6nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089066(CHEMBL276768 | Naphthalene-1-sulfonic acid (4-{[(4...)
Show SMILES CN(C[C@H]1CC[C@H](CNS(=O)(=O)c2cccc3ccccc23)CC1)c1nc(N)c2ccccc2n1
Show InChI InChI=1S/C27H31N5O2S/c1-32(27-30-24-11-5-4-10-23(24)26(28)31-27)18-20-15-13-19(14-16-20)17-29-35(33,34)25-12-6-8-21-7-2-3-9-22(21)25/h2-12,19-20,29H,13-18H2,1H3,(H2,28,30,31)/t19-,20-
Affinity DataIC50: 16nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089050(CHEMBL16936 | N*2*-(4-Cyclohexyl-phenyl)-N*4*-phen...)
Show SMILES C1CCC(CC1)c1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C26H26N4/c1-3-9-19(10-4-1)20-15-17-22(18-16-20)28-26-29-24-14-8-7-13-23(24)25(30-26)27-21-11-5-2-6-12-21/h2,5-8,11-19H,1,3-4,9-10H2,(H2,27,28,29,30)
Affinity DataIC50: 20nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089058(CHEMBL276551 | Naphthalene-1-sulfonic acid [6-(4-a...)
Show SMILES Nc1nc(NCCCCCCNS(=O)(=O)c2cccc3ccccc23)nc2ccccc12
Show InChI InChI=1S/C24H27N5O2S/c25-23-20-13-5-6-14-21(20)28-24(29-23)26-16-7-1-2-8-17-27-32(30,31)22-15-9-11-18-10-3-4-12-19(18)22/h3-6,9-15,27H,1-2,7-8,16-17H2,(H3,25,26,28,29)
Affinity DataIC50: 28nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089054(CHEMBL17352 | N*2*-(4-Methoxy-phenyl)-N*4*-phenyl-...)
Show SMILES COc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C21H18N4O/c1-26-17-13-11-16(12-14-17)23-21-24-19-10-6-5-9-18(19)20(25-21)22-15-7-3-2-4-8-15/h2-14H,1H3,(H2,22,23,24,25)
Affinity DataIC50: 33nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089044(CHEMBL17686 | [4-(4-Phenylamino-quinazolin-2-ylami...)
Show SMILES CCOP(=O)(Cc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1)OCC
Show InChI InChI=1S/C25H27N4O3P/c1-3-31-33(30,32-4-2)18-19-14-16-21(17-15-19)27-25-28-23-13-9-8-12-22(23)24(29-25)26-20-10-6-5-7-11-20/h5-17H,3-4,18H2,1-2H3,(H2,26,27,28,29)
Affinity DataIC50: 33nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089033(CHEMBL418359 | Naphthalene-1-sulfonic acid {3-[(4-...)
Show SMILES Nc1nc(NCC2CCCC(CNS(=O)(=O)c3cccc4ccccc34)C2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-12-3-4-13-23(22)30-26(31-25)28-16-18-7-5-8-19(15-18)17-29-34(32,33)24-14-6-10-20-9-1-2-11-21(20)24/h1-4,6,9-14,18-19,29H,5,7-8,15-17H2,(H3,27,28,30,31)
Affinity DataIC50: 38nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089045(CHEMBL17196 | Naphthalene-1-sulfonic acid [7-(4-am...)
Show SMILES Nc1nc(NCCCCCCCNS(=O)(=O)c2cccc3ccccc23)nc2ccccc12
Show InChI InChI=1S/C25H29N5O2S/c26-24-21-14-6-7-15-22(21)29-25(30-24)27-17-8-2-1-3-9-18-28-33(31,32)23-16-10-12-19-11-4-5-13-20(19)23/h4-7,10-16,28H,1-3,8-9,17-18H2,(H3,26,27,29,30)
Affinity DataIC50: 44nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089037(CHEMBL17701 | Naphthalene-1-sulfonic acid [8-(4-am...)
Show SMILES Nc1nc(NCCCCCCCCNS(=O)(=O)c2cccc3ccccc23)nc2ccccc12
Show InChI InChI=1S/C26H31N5O2S/c27-25-22-15-7-8-16-23(22)30-26(31-25)28-18-9-3-1-2-4-10-19-29-34(32,33)24-17-11-13-20-12-5-6-14-21(20)24/h5-8,11-17,29H,1-4,9-10,18-19H2,(H3,27,28,30,31)
Affinity DataIC50: 46nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089046(CHEMBL17022 | Naphthalene-2-sulfonic acid (4-{[(na...)
Show SMILES O=S(=O)(NC[C@H]1CC[C@H](CNCc2ccc3ccccc3c2)CC1)c1ccc2ccccc2c1
Show InChI InChI=1S/C29H32N2O2S/c32-34(33,29-16-15-26-6-2-4-8-28(26)18-29)31-21-23-11-9-22(10-12-23)19-30-20-24-13-14-25-5-1-3-7-27(25)17-24/h1-8,13-18,22-23,30-31H,9-12,19-21H2/t22-,23-
Affinity DataIC50: 47nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089047(CHEMBL17914 | N*2*-Cyclohexyl-N*4*-phenyl-quinazol...)
Show SMILES C1CCC(CC1)Nc1nc(Nc2ccccc2)c2ccccc2n1
Show InChI InChI=1S/C20H22N4/c1-3-9-15(10-4-1)21-19-17-13-7-8-14-18(17)23-20(24-19)22-16-11-5-2-6-12-16/h1,3-4,7-10,13-14,16H,2,5-6,11-12H2,(H2,21,22,23,24)
Affinity DataIC50: 50nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089043(CHEMBL17417 | N*2*-{2-[1-(Naphthalene-1-sulfonyl)-...)
Show SMILES Nc1nc(NCCC2CCN(CC2)S(=O)(=O)c2cccc3ccccc23)nc2ccccc12
Show InChI InChI=1S/C25H27N5O2S/c26-24-21-9-3-4-10-22(21)28-25(29-24)27-15-12-18-13-16-30(17-14-18)33(31,32)23-11-5-7-19-6-1-2-8-20(19)23/h1-11,18H,12-17H2,(H3,26,27,28,29)
Affinity DataIC50: 51nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089032(CHEMBL17395 | N-{4-[4-(4-Chloro-phenylamino)-quina...)
Show SMILES CN(C[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(Cl)cc2)c2ccccc2n1)C(C)=O
Show InChI InChI=1S/C24H28ClN5O/c1-16(31)30(2)15-17-7-11-20(12-8-17)27-24-28-22-6-4-3-5-21(22)23(29-24)26-19-13-9-18(25)10-14-19/h3-6,9-10,13-14,17,20H,7-8,11-12,15H2,1-2H3,(H2,26,27,28,29)/t17-,20-
Affinity DataIC50: 58nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089040(CHEMBL17483 | N*2*,N*4*-Diphenyl-quinazoline-2,4-d...)
Show SMILES N(c1ccccc1)c1nc(Nc2ccccc2)c2ccccc2n1
Show InChI InChI=1S/C20H16N4/c1-3-9-15(10-4-1)21-19-17-13-7-8-14-18(17)23-20(24-19)22-16-11-5-2-6-12-16/h1-14H,(H2,21,22,23,24)
Affinity DataIC50: 80nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089067(CHEMBL17326 | N*2*-(4-Chloro-phenyl)-N*4*-phenyl-q...)
Show SMILES Clc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C20H15ClN4/c21-14-10-12-16(13-11-14)23-20-24-18-9-5-4-8-17(18)19(25-20)22-15-6-2-1-3-7-15/h1-13H,(H2,22,23,24,25)
Affinity DataIC50: 100nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089051(CHEMBL17911 | Naphthalene-1-sulfonic acid {4-[(4-a...)
Show SMILES CN(C[C@H]1CC[C@H](CNc2nc(N)c3ccccc3n2)CC1)S(=O)(=O)c1cccc2ccccc12
Show InChI InChI=1S/C27H31N5O2S/c1-32(35(33,34)25-12-6-8-21-7-2-3-9-22(21)25)18-20-15-13-19(14-16-20)17-29-27-30-24-11-5-4-10-23(24)26(28)31-27/h2-12,19-20H,13-18H2,1H3,(H3,28,29,30,31)/t19-,20-
Affinity DataIC50: 110nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089062(1'-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-4-cyclo...)
Show SMILES COc1cc2nc(nc(N)c2cc1OC)N1CCC(CC1)N1C(=O)CC(CC1=O)C1CCCCC1
Show InChI InChI=1S/C26H35N5O4/c1-34-21-14-19-20(15-22(21)35-2)28-26(29-25(19)27)30-10-8-18(9-11-30)31-23(32)12-17(13-24(31)33)16-6-4-3-5-7-16/h14-18H,3-13H2,1-2H3,(H2,27,28,29)
Affinity DataIC50: 160nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089057(CHEMBL429053 | N*4*-Phenyl-N*2*-p-tolyl-quinazolin...)
Show SMILES Cc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1
Show InChI InChI=1S/C21H18N4/c1-15-11-13-17(14-12-15)23-21-24-19-10-6-5-9-18(19)20(25-21)22-16-7-3-2-4-8-16/h2-14H,1H3,(H2,22,23,24,25)
Affinity DataIC50: 200nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089061(CHEMBL17450 | N*2*-(3-Dibutylamino-propyl)-N*4*-(3...)
Show SMILES CCCCN(CCCC)CCCNc1nc(Nc2cccc(c2)C(F)(F)F)c2ccccc2n1
Show InChI InChI=1S/C26H34F3N5/c1-3-5-16-34(17-6-4-2)18-10-15-30-25-32-23-14-8-7-13-22(23)24(33-25)31-21-12-9-11-20(19-21)26(27,28)29/h7-9,11-14,19H,3-6,10,15-18H2,1-2H3,(H2,30,31,32,33)
Affinity DataIC50: 210nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089031(CHEMBL17427 | N-{4-[4-(4-Chloro-phenylamino)-quina...)
Show SMILES CN(C[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(Cl)cc2)c2ccccc2n1)C(=O)c1ccccc1
Show InChI InChI=1S/C29H30ClN5O/c1-35(28(36)21-7-3-2-4-8-21)19-20-11-15-24(16-12-20)32-29-33-26-10-6-5-9-25(26)27(34-29)31-23-17-13-22(30)14-18-23/h2-10,13-14,17-18,20,24H,11-12,15-16,19H2,1H3,(H2,31,32,33,34)/t20-,24-
Affinity DataIC50: 250nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089034(CHEMBL17247 | N*2*-(3,4-Dichloro-phenyl)-N*4*-phen...)
Show SMILES Clc1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1Cl
Show InChI InChI=1S/C20H14Cl2N4/c21-16-11-10-14(12-17(16)22)24-20-25-18-9-5-4-8-15(18)19(26-20)23-13-6-2-1-3-7-13/h1-12H,(H2,23,24,25,26)
Affinity DataIC50: 270nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089053(CHEMBL278677 | Naphthalene-1-sulfonic acid 4-[(4-a...)
Show SMILES Nc1nc(NCc2ccc(CNS(=O)(=O)c3cccc4ccccc34)cc2)nc2ccccc12
Show InChI InChI=1S/C26H23N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-15,29H,16-17H2,(H3,27,28,30,31)
Affinity DataIC50: 290nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089056(CHEMBL279181 | N-{4-[4-(4-Chloro-phenylamino)-quin...)
Show SMILES Clc1ccc(Nc2nc(N[C@H]3CC[C@H](CNC(=O)c4ccccc4)CC3)nc3ccccc23)cc1
Show InChI InChI=1S/C28H28ClN5O/c29-21-12-16-22(17-13-21)31-26-24-8-4-5-9-25(24)33-28(34-26)32-23-14-10-19(11-15-23)18-30-27(35)20-6-2-1-3-7-20/h1-9,12-13,16-17,19,23H,10-11,14-15,18H2,(H,30,35)(H2,31,32,33,34)/t19-,23-
Affinity DataIC50: 310nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089059(CHEMBL16965 | Naphthalene-1-sulfonic acid 3-[(4-am...)
Show SMILES Nc1nc(NCc2cccc(CNS(=O)(=O)c3cccc4ccccc34)c2)nc2ccccc12
Show InChI InChI=1S/C26H23N5O2S/c27-25-22-12-3-4-13-23(22)30-26(31-25)28-16-18-7-5-8-19(15-18)17-29-34(32,33)24-14-6-10-20-9-1-2-11-21(20)24/h1-15,29H,16-17H2,(H3,27,28,30,31)
Affinity DataIC50: 380nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089042(CHEMBL17398 | N-{4-[4-(4-Chloro-phenylamino)-quina...)
Show SMILES CC(=O)NC[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(Cl)cc2)c2ccccc2n1
Show InChI InChI=1S/C23H26ClN5O/c1-15(30)25-14-16-6-10-19(11-7-16)27-23-28-21-5-3-2-4-20(21)22(29-23)26-18-12-8-17(24)9-13-18/h2-5,8-9,12-13,16,19H,6-7,10-11,14H2,1H3,(H,25,30)(H2,26,27,28,29)/t16-,19-
Affinity DataIC50: 390nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089052(Benzoic acid 4-(4-phenylamino-quinazolin-2-ylamino...)
Show SMILES O=C(O[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ccccc2n1)c1ccccc1
Show InChI InChI=1S/C27H26N4O2/c32-26(19-9-3-1-4-10-19)33-22-17-15-21(16-18-22)29-27-30-24-14-8-7-13-23(24)25(31-27)28-20-11-5-2-6-12-20/h1-14,21-22H,15-18H2,(H2,28,29,30,31)/t21-,22-
Affinity DataIC50: 400nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089049(CHEMBL17454 | N*4*-(4-Chloro-phenyl)-N*2*-(4-methy...)
Show SMILES CNC[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(Cl)cc2)c2ccccc2n1
Show InChI InChI=1S/C22H26ClN5/c1-24-14-15-6-10-18(11-7-15)26-22-27-20-5-3-2-4-19(20)21(28-22)25-17-12-8-16(23)9-13-17/h2-5,8-9,12-13,15,18,24H,6-7,10-11,14H2,1H3,(H2,25,26,27,28)/t15-,18-
Affinity DataIC50: 510nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089064(CHEMBL275845 | Naphthalene-1-sulfonic acid (4-{[(4...)
Show SMILES CN(C[C@H]1CC[C@H](CN(C)S(=O)(=O)c2cccc3ccccc23)CC1)c1nc(N)c2ccccc2n1
Show InChI InChI=1S/C28H33N5O2S/c1-32(28-30-25-12-6-5-11-24(25)27(29)31-28)18-20-14-16-21(17-15-20)19-33(2)36(34,35)26-13-7-9-22-8-3-4-10-23(22)26/h3-13,20-21H,14-19H2,1-2H3,(H2,29,30,31)/t20-,21-
Affinity DataIC50: 710nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089061(CHEMBL17450 | N*2*-(3-Dibutylamino-propyl)-N*4*-(3...)
Show SMILES CCCCN(CCCC)CCCNc1nc(Nc2cccc(c2)C(F)(F)F)c2ccccc2n1
Show InChI InChI=1S/C26H34F3N5/c1-3-5-16-34(17-6-4-2)18-10-15-30-25-32-23-14-8-7-13-22(23)24(33-25)31-21-12-9-11-20(19-21)26(27,28)29/h7-9,11-14,19H,3-6,10,15-18H2,1-2H3,(H2,30,31,32,33)
Affinity DataIC50: 1.00E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089041(CHEMBL275610 | [1-(Naphthalene-1-sulfonyl)-piperid...)
Show SMILES O=S(=O)(N1CCC(CNCc2ccc3ccccc3c2)CC1)c1cccc2ccccc12
Show InChI InChI=1S/C27H28N2O2S/c30-32(31,27-11-5-9-24-7-3-4-10-26(24)27)29-16-14-21(15-17-29)19-28-20-22-12-13-23-6-1-2-8-25(23)18-22/h1-13,18,21,28H,14-17,19-20H2
Affinity DataIC50: 1.00E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089035(2-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piper...)
Show SMILES COc1cc2nc(nc(N)c2cc1OC)N1CCC(CC1)N1Cc2ccccc2C1=O
Show InChI InChI=1S/C23H25N5O3/c1-30-19-11-17-18(12-20(19)31-2)25-23(26-21(17)24)27-9-7-15(8-10-27)28-13-14-5-3-4-6-16(14)22(28)29/h3-6,11-12,15H,7-10,13H2,1-2H3,(H2,24,25,26)
Affinity DataIC50: 1.40E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 2(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 1.89E+3nMAssay Description:Compound was tested for human Neuropeptide Y receptor type 2More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089039(CHEMBL17441 | N*2*-(4-Amino-butyl)-6-phenyl-quinaz...)
Show SMILES NCCCCNc1nc(N)c2cc(ccc2n1)-c1ccccc1
Show InChI InChI=1S/C18H21N5/c19-10-4-5-11-21-18-22-16-9-8-14(12-15(16)17(20)23-18)13-6-2-1-3-7-13/h1-3,6-9,12H,4-5,10-11,19H2,(H3,20,21,22,23)
Affinity DataIC50: 2.00E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 5More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089068(CHEMBL277551 | Naphthalene-1-sulfonic acid [(1R,2S...)
Show SMILES Nc1nc(N[C@H]2CCCC[C@H]2NS(=O)(=O)c2cccc3ccccc23)nc2ccccc12
Show InChI InChI=1S/C24H25N5O2S/c25-23-18-11-3-4-12-19(18)26-24(28-23)27-20-13-5-6-14-21(20)29-32(30,31)22-15-7-9-16-8-1-2-10-17(16)22/h1-4,7-12,15,20-21,29H,5-6,13-14H2,(H3,25,26,27,28)/t20-,21+/m0/s1
Affinity DataIC50: 4.90E+3nMAssay Description:Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cellsMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 4(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 5.74E+3nMAssay Description:Compound was tested for human Neuropeptide Y receptor type 4More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089039(CHEMBL17441 | N*2*-(4-Amino-butyl)-6-phenyl-quinaz...)
Show SMILES NCCCCNc1nc(N)c2cc(ccc2n1)-c1ccccc1
Show InChI InChI=1S/C18H21N5/c19-10-4-5-11-21-18-22-16-9-8-14(12-15(16)17(20)23-18)13-6-2-1-3-7-13/h1-3,6-9,12H,4-5,10-11,19H2,(H3,20,21,22,23)
Affinity DataIC50: 8.00E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089038(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
Affinity DataIC50: 8.37E+3nMAssay Description:Compound was tested for human Neuropeptide Y receptor type 1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089062(1'-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-4-cyclo...)
Show SMILES COc1cc2nc(nc(N)c2cc1OC)N1CCC(CC1)N1C(=O)CC(CC1=O)C1CCCCC1
Show InChI InChI=1S/C26H35N5O4/c1-34-21-14-19-20(15-22(21)35-2)28-26(29-25(19)27)30-10-8-18(9-11-30)31-23(32)12-17(13-24(31)33)16-6-4-3-5-7-16/h14-18H,3-13H2,1-2H3,(H2,27,28,29)
Affinity DataIC50: 8.90E+3nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089046(CHEMBL17022 | Naphthalene-2-sulfonic acid (4-{[(na...)
Show SMILES O=S(=O)(NC[C@H]1CC[C@H](CNCc2ccc3ccccc3c2)CC1)c1ccc2ccccc2c1
Show InChI InChI=1S/C29H32N2O2S/c32-34(33,29-16-15-26-6-2-4-8-28(26)18-29)31-21-23-11-9-22(10-12-23)19-30-20-24-13-14-25-5-1-3-7-27(25)17-24/h1-8,13-18,22-23,30-31H,9-12,19-21H2/t22-,23-
Affinity DataIC50: 1.00E+4nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Novartis Pharma AG

Curated by ChEMBL
LigandPNGBDBM50089035(2-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piper...)
Show SMILES COc1cc2nc(nc(N)c2cc1OC)N1CCC(CC1)N1Cc2ccccc2C1=O
Show InChI InChI=1S/C23H25N5O3/c1-30-19-11-17-18(12-20(19)31-2)25-23(26-21(17)24)27-9-7-15(8-10-27)28-13-14-5-3-4-6-16(14)22(28)29/h3-6,11-12,15H,7-10,13H2,1-2H3,(H2,24,25,26)
Affinity DataIC50: 6.00E+4nMAssay Description:Compound was tested for its affinity to bind with Neuropeptide Y receptor type 1More data for this Ligand-Target Pair